Bayer introduces versatile new option for heartworm prevention and intestinal parasite control

Coraxis™ (moxidectin) Topical Solution for Dogs provides veterinarians with 30-day heartworm protection and treats and controls hookworms, roundworms and whipworms

News provided by

Bayer

Jan 18, 2019, 14:01 ET

SHAWNEE, Kan., Jan. 18, 2019 /PRNewswire/ -- Bayer Animal Health announces the launch of Coraxis™ (moxidectin) Topical Solution for Dogs, a prescription-only, monthly transdermal product that prevents heartworm disease and treats and controls hookworms, roundworms, and whipworms in dogs. The product is expected to be available for sale in early February.

"Coraxis™ is a unique addition to the veterinarian's anti-parasite toolbox," said Robert Zolynas, DVM, MBA, Head of Research and Development North America for Bayer Animal Health. "Its transdermal formulation is rapidly absorbed, achieving and sustaining high plasma levels of moxidectin to continuously kill incoming heartworm larvae for thirty days. This important feature along with its broad-spectrum intestinal worm protection, make it a versatile and useful product."

Administered monthly, Coraxis™ is a prescription drug that should be administered on the order of a veterinarian. It provides veterinarians more flexibility in creating parasite protection plans for dogs. Coraxis™ is available in five different sizes and is for use in dogs and puppies 7 weeks of age and older weighing between 3 to 110 pounds.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.

Contact:
Kerry Johnson
Bayer Animal Health
Email: [email protected]
Mobile: 913-530-3345

Social Media Channels
- Twitter: @Bayer4Pets
- Instagram: @Bayer4Pets

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

©2019 Bayer, Shawnee Mission, Kansas 66201
Bayer (reg'd), the Bayer Cross (reg'd) and Coraxis^TM are trademarks of Bayer. CX19813

CAUTION: Federal (U.S.A.) law restricts Coraxis^TM to use by or on the order of a licensed veterinarian. WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) CONTRAINDICATIONS: Do not use this product on cats.

SOURCE Bayer